Leerink Analyst Says Prescriptions for Amarin's Vascepa 'Tracking Well'
Leerink Swann's Joseph Schwartz issued a note earlier Monday suggesting prescriptions for Amarin's (NASDAQ: AMRN) Vascepa are "tracking well."
The analyst said recent IMS data showed Vascepa prescriptions through the eleventh week are at 1,504 per week. Refills are at 13 percent. Schwartz called this level of prescriptions to be in inline with several other recent cardiovascular-related oral drug offerings.
Schwartz believes the next major catalyst for Amarin will be the sNDA for usage in mixed dyslipidemia and FDA acceptance in late April or early May.
Schwartz maintains an Outperform rating on shares of Amarin.
Shares of Amarin are up 0.1 percent to $7.42 at last check.
Latest Ratings for AMRN
|Feb 2014||Aegis Capital||Maintains||Hold|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.